Genome Editing / Genome Engineering: Global Strategic Business Report

Report
187 Pages
April 2024
Region: Global
Global Industry Analysts, Inc
ID: 4805049

Global Genome Editing / Genome Engineering Market to Reach $34.3 Billion by 2030

The global market for Genome Editing / Genome Engineering estimated at US$8 Billion in the year 2022, is projected to reach a revised size of US$34.3 Billion by 2030, growing at a CAGR of 19.9% over the analysis period 2022-2030. CRISPR, one of the segments analyzed in the report, is projected to record 22.4% CAGR and reach US$16.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the ZFN segment is readjusted to a revised 15% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2.5 Billion, While China is Forecast to Grow at 19.2% CAGR

The Genome Editing / Genome Engineering market in the U.S. is estimated at US$2.5 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 19.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.4% and 16.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 13.5% CAGR.

Select Competitors (Total 27 Featured) -

CRISPR Therapeutics AG
Editas Medicine, Inc.
GenScript Biotech Corporation
Horizon Discovery Group PLC
Integrated DNA Technologies (IDT), Inc.
Lonza Group AG
Merck & Co., Inc.
New England Biolabs, Inc.
OriGene Technologies, Inc.
Sangamo Therapeutics
Thermo Fisher Scientific, Inc.
Transposagen Biopharmaceuticals, Inc.

What's New?

Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to digital archives and Research Platform
Complimentary updates for one year

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
Genome Editing / Genome Engineering - Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 2: World 8-Year Perspective for Genome Editing / Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
Table 3: World Recent Past, Current & Future Analysis for CRISPR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 4: World 8-Year Perspective for CRISPR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
Table 5: World Recent Past, Current & Future Analysis for TALEN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 6: World 8-Year Perspective for TALEN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for ZFN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 8: World 8-Year Perspective for ZFN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
Table 9: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 10: World 8-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
Table 11: World Genome Editing / Genome Engineering Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
Table 12: World Recent Past, Current & Future Analysis for Ex-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 13: World 8-Year Perspective for Ex-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
Table 14: World Recent Past, Current & Future Analysis for In-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 15: World 8-Year Perspective for In-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for Genetic Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 17: World 8-Year Perspective for Genetic Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
Table 18: World Recent Past, Current & Future Analysis for Clinical Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 19: World 8-Year Perspective for Clinical Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
Table 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 21: World 8-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
Table 22: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 23: World 8-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
Table 24: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 25: World 8-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

UNITED STATES

Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
Table 26: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 27: USA 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 28: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 29: USA 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 30: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 31: USA 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 32: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 33: USA 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

CANADA

Table 34: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 35: Canada 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 36: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 37: Canada 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 38: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 39: Canada 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 40: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 41: Canada 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

JAPAN

Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 42: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 43: Japan 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 44: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 45: Japan 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 46: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 47: Japan 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 48: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 49: Japan 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

CHINA

Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
Table 50: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 51: China 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 52: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 53: China 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 54: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 55: China 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 56: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 57: China 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

EUROPE

Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 58: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 59: Europe 8-Year Perspective for Genome Editing / Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
Table 60: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 61: Europe 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 62: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 63: Europe 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 64: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 65: Europe 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 66: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 67: Europe 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

FRANCE

Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
Table 68: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 69: France 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 70: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 71: France 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 72: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 73: France 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 74: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 75: France 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

GERMANY

Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 76: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 77: Germany 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 78: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 79: Germany 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 80: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 81: Germany 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 82: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 83: Germany 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

ITALY

Table 84: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 85: Italy 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 86: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 87: Italy 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 88: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 89: Italy 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 90: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 91: Italy 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

UNITED KINGDOM

Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 92: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 93: UK 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 94: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 95: UK 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 96: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 97: UK 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 98: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 99: UK 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

REST OF EUROPE

Table 100: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 101: Rest of Europe 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 102: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 103: Rest of Europe 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 104: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 105: Rest of Europe 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 106: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 107: Rest of Europe 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

ASIA-PACIFIC

Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 108: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 109: Asia-Pacific 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 111: Asia-Pacific 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 112: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 113: Asia-Pacific 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 114: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 115: Asia-Pacific 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

REST OF WORLD

Table 116: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 117: Rest of World 8-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2023 & 2030
Table 118: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 119: Rest of World 8-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2023 & 2030
Table 120: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 121: Rest of World 8-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2023 & 2030
Table 122: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 123: Rest of World 8-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2023 & 2030

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

CRISPR Therapeutics AG
Editas Medicine, Inc.
GenScript Biotech Corporation
Horizon Discovery Group PLC
Integrated DNA Technologies (IDT), Inc.
Lonza Group AG
Merck & Co., Inc.
New England Biolabs, Inc.
OriGene Technologies, Inc.
Sangamo Therapeutics
Thermo Fisher Scientific, Inc.
Transposagen Biopharmaceuticals, Inc.

Table Information

Report Attribute	Details
No. of Pages	187
Published	April 2024
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 8 Billion
Forecasted Market Value ( USD ) by 2030	$ 34.3 Billion
Compound Annual Growth Rate	20.0%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF

1 - 10 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4828EUR$4,950USD£4,122GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€9174EUR$9,405USD£7,833GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€14485EUR$14,850USD£12,367GBP

Global Genome Editing / Genome Engineering Market to Reach $34.3 Billion by 2030

The U.S. Market is Estimated at $2.5 Billion, While China is Forecast to Grow at 19.2% CAGR

Select Competitors (Total 27 Featured) -

What's New?

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR, ZFN, TALEN), By Delivery Method (Ex-vivo, In-vivo), By Application, By Mode, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Global Genome Editing/Genome Engineering Market by Application, Technology, and End User, Regional Outlook - Forecast up to 2030

Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts

Genome Editing/Genome Engineering Global Market Report 2024

Genome Editing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F